XOMA Corp - Multiplikator nilai perusahaan marang pendapatan XOMA

XOMA Corporation (XOMA) - logo korporat

Digital license management without owning manufacturing plants defines the operational split of XOMA Royalty (XOMA). The enterprise value-to-annual revenue multiple on the GURU.Markets chart demonstrates the asset's dynamics, where 15654.99 forms the current metric value. Market capitalization relies on confidence in early-stage development financing methods, while profit is generated through the ownership of sales rights for approved pharmaceutical drugs.

XOMA: Rasio nilai perusahaan marang pendapatan XOMA Corp 23.11.2025 - 25.07.2026

XOMA Royalty - rincian analitis lan metrik utama (XOMA)

- nilai pasar lan prakiraan target analis:
- indikator dhuwit lan arus kas:
Pambiji fundamental:XOMA Corp XOMA
Produk asil prodhuksi XOMA Corp

The XOMA Royalty (XOMA) biotech royalty model minimizes operating expenses by transferring regulatory risks to partners. The EV/Sales metric compares the total enterprise value, adjusted for net debt, against the volume of generated revenue. This calculation helps identify asset overvaluation during periods of market volatility. It is critical for investors to monitor this balance to avoid capital freezing. The current EV/Sales level objectifies the value of the company's exclusive rights to future drug sales.